Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengqing Fentongning Tablets
- Development stage
- Unknown
- Lead developer
- Zhengqing Pharmaceutical Group
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Zhengqing Fentongning Tablets (also known as Zhengqing Fengtongning Tablets) is an approved traditional Chinese medicine (TCM) formulation developed by Hunan Zhengqing Pharmaceutical Group. The active pharmaceutical ingredient is sinomenine hydrochloride, a pure alkaloid extracted from the medicinal plant *Sinomenium acutum* (Qing Feng Teng). It is widely used in China for the treatment of rheumatic diseases, rheumatoid arthritis, and osteoarthritis. Sinomenine hydrochloride exerts its therapeutic effects through anti-inflammatory, analgesic, and immunomodulatory mechanisms, which include acting as an agonist of the alpha7 nicotinic acetylcholine receptor (CHRNA7) and the aryl hydrocarbon receptor (AHR), activating the mu-type opioid receptor (OPRM1), and directly binding to and inhibiting guanylate-binding protein 5 (GBP5) to suppress the NLRP3 inflammasome pathway.
- Brand names
- XiluomingZhengqing
- Other names
- Zhengqing Fengtongning Tabletssinomenine hydrochloride tablets正清风痛宁片
02
Targets
MOR (Mu opioid receptor)CHRNA7 (α7 nicotinic receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Zhengqing Fentongning Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhengqing Fentongning Tablets.